ProVise Management Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.95M Buy
140,662
+4,942
+4% +$132K 0.28% 78
2025
Q4
$3.38M Buy
135,720
+5,351
+4% +$135K 0.24% 82
2025
Q3
$3.32M Sell
130,369
-2,512
-2% -$62K 0.24% 84
2025
Q2
$3.22M Buy
132,881
+18,724
+16% +$437K 0.25% 84
2025
Q1
$2.89M Buy
114,157
+7,327
+7% +$192K 0.25% 85
2024
Q4
$2.83M Sell
106,830
-23,582
-18% -$640K 0.24% 89
2024
Q3
$3.77M Buy
130,412
+1,486
+1% +$43.3K 0.3% 87
2024
Q2
$3.61M Buy
128,926
+2,131
+2% +$58.7K 0.31% 85
2024
Q1
$3.52M Sell
126,795
-3,684
-3% -$102K 0.3% 86
2023
Q4
$3.76M Sell
130,479
-5,116
-4% -$155K 0.32% 88
2023
Q3
$4.5M Buy
135,595
+3,827
+3% +$135K 0.42% 70
2023
Q2
$4.83M Buy
131,768
+3,134
+2% +$122K 0.44% 67
2023
Q1
$5.25M Sell
128,634
-112,056
-47% -$4.84M 0.5% 63
2022
Q4
$12.3M Sell
240,690
-6,330
-3% -$303K 1.25% 23
2022
Q3
$10.8M Buy
247,020
+3,045
+1% +$148K 1.21% 19
2022
Q2
$12.8M Buy
243,975
+2,579
+1% +$131K 1.36% 17
2022
Q1
$12.5M Buy
241,396
+2,204
+0.9% +$114K 1.18% 19
2021
Q4
$14.1M Buy
239,192
+694
+0.3% +$34.4K 1.28% 15
2021
Q3
$10.3M Buy
238,498
+4,477
+2% +$198K 1.01% 20
2021
Q2
$9.16M Buy
234,021
+4,566
+2% +$178K 0.93% 21
2021
Q1
$8.31M Buy
229,455
+2,423
+1% +$86K 0.9% 23
2020
Q4
$8.36M Sell
227,032
-8,485
-4% -$311K 0.96% 22
2020
Q3
$8.2M Sell
235,517
-213
-0.1% -$7.47K 1.1% 19
2020
Q2
$7.31M Sell
235,730
-7,350
-3% -$250K 1.05% 21
2020
Q1
$7.53M Sell
243,080
-3,304
-1% -$113K 1.26% 16
2019
Q4
$9.16M Buy
246,384
+2,624
+1% +$93.5K 1.13% 22
2019
Q3
$8.31M Buy
243,760
+1,875
+0.8% +$68.2K 1.1% 21
2019
Q2
$9.94M Buy
241,885
+5,628
+2% +$223K 1.33% 14
2019
Q1
$9.52M Sell
236,257
-7,644
-3% -$306K 1.34% 14
2018
Q4
$10.1M Sell
243,901
-9,199
-4% -$382K 1.6% 12
2018
Q3
$10.6M Sell
253,100
-3,621
-1% -$139K 1.39% 13
2018
Q2
$23.3K Buy
256,721
+1,144
+0.4% +$39.1K 1.76% 9
2018
Q1
$8.61M Sell
255,577
-2,653
-1% -$91.2K 1.27% 17
2017
Q4
$8.87M Sell
258,230
-10,510
-4% -$358K 1.27% 18
2017
Q3
$9.1M Buy
268,740
+11,484
+4% +$369K 1.32% 15
2017
Q2
$8.2M Buy
257,256
+14,351
+6% +$453K 1.24% 17
2017
Q1
$7.88M Buy
242,905
+6,431
+3% +$203K 1.27% 13
2016
Q4
$7.29M Buy
236,474
+6,941
+3% +$212K 1.24% 14
2016
Q3
$7.38M Buy
229,533
+32,229
+16% +$1.08M 1.28% 13
2016
Q2
$6.59M Buy
197,304
+54,794
+38% +$1.75M 1.21% 13
2016
Q1
$4.01M Buy
142,510
+12,901
+10% +$369K 0.82% 32
2015
Q4
$3.97M Buy
129,609
+780
+0.6% +$24.5K 0.83% 28
2015
Q3
$3.84M Sell
128,829
-275
-0.2% -$8.82K 0.89% 27
2015
Q2
$4.11M Buy
129,104
+2,344
+2% +$76.4K 0.87% 28
2015
Q1
$4.18M Sell
126,760
-368
-0.3% -$11.7K 0.89% 25
2014
Q4
$3.76M Sell
127,128
-1,643
-1% -$47.1K 0.81% 31
2014
Q3
$3.61M Sell
128,771
-10,610
-8% -$298K 0.78% 30
2014
Q2
$3.92M Sell
139,381
-710
-0.5% -$20.2K 0.85% 29
2014
Q1
$4.27M Buy
140,091
+4,263
+3% +$127K 1.03% 21
2013
Q4
$3.95M Sell
135,828
-15,002
-10% -$437K 1.02% 15
2013
Q3
$4.11M Sell
150,830
-3,976
-3% -$108K 1.16% 11
2013
Q2
$4.11M Buy
+154,806
New +$4.28M 1.21% 10

Other funds holding PFE

ProVise Management Group's PFE Position: Q1 2026 in Review

ProVise Management Group increased its Pfizer (PFE) stake by 3.6% in Q1 2026, buying an estimated $132K and bringing the position to 140,662 shares worth $3.95M. The position accounts for 0.28% of the portfolio, ranked #78.

ProVise Management Group first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $14.1M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • ProVise Management Group held 140,662 shares of Pfizer worth $3.95M as of Q1 2026.
  • ProVise Management Group bought 4,942 Pfizer shares in Q1 2026, an estimated $132K.
  • Pfizer made up 0.28% of ProVise Management Group's portfolio in Q1 2026, its #78 holding.
  • ProVise Management Group first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • ProVise Management Group's Pfizer position peaked at $14.1M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on ProVise Management Group's 13F filing for Q1 2026, filed 7 May 2026.